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Platelets express a variety of polymorphic glycoproteins (GPs), 
such as GPIIb/IIIa, GPIb/IX, GPIa/IIa, GPIV, and class I 
human leukocyte antigen. In the platelet transfusion setting, 
alloimmunization involves the production of antibodies against 
these glycoproteins. Patients transfused with multiple units of 
platelet concentrates for longer periods are the main individuals 
with platelet alloimmunization. This study was performed to 
detect the development of platelet antibodies in patients who 
are transfused with multiple units of leukodepleted platelet 
concentrates, such as those with hemato-oncologic diseases and 
bone marrow failure syndromes. The method used was solid-
phase modified antigen capture enzyme-linked immunosorbent 
assay. Platelet refractoriness was assessed by measuring the 
corrected count increment at 1 and 24 hours after transfusion. 
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Platelets express a variety of polymorphic glycoproteins 
(GPs), such as GPIIb/IIIa, GPIb/IX, GPIa/IIa, GPIV, and class 
I human leukocyte antigen (HLA).1 In the platelet transfusion 
setting, alloimmunization involves the production of antibodies 
against these glycoproteins. Patients transfused with multiple 
units of platelet concentrates for longer periods are the main 
individuals with platelet alloimmunization. Approximately 
20 to 85 percent of patients who receive multiple platelet 
transfusions become immunized against platelet antigens, and 
approximately 40 percent of patients who are alloimmunized 
exhibit refractoriness to platelet transfusions.2 Among patients 
receiving long-term blood component support, refractoriness 
to platelet transfusions may be observed in 10 to 70 percent, 
of which HLA antibodies can be found in 20 to 70 percent of 
patients.3
There are three groups of assays currently available to 
detect platelet antibodies. The earliest were phase I assays that 
involved mixing patient serum with normal platelets and used 
platelet function–dependent end points such as alpha granule 
release, aggregation, or agglutination. These were followed by 
phase II assays that measured either surface or total platelet-
associated immunoglobulin on patient or normal platelets after 
sensitization with patient serum. Recently, phase III assays 
have been developed that require the binding and detection 
of antibodies to isolated platelet surface glycoproteins (GPs) or 
HLA class-1 antigens.
Materials and Methods
The study was carried out in the Department of 
Immunohaematology and Blood Transfusion of a tertiary-care 
hospital in Pune, Western India, from June 2010 to May 2012. 
The study was carried out after receiving approval from the 
institutional ethical committee and informed consent from the 
patients.
A total of 100 patients who had been transfused with 
at least 15 units of leukodepleted platelet concentrate were 
selected. All patients had either hematologic malignancies or 
bone marrow failure syndromes.
Testing was performed using the solid-phase modified 
antigen capture enzyme-linked immunosorbent assay (ELISA) 
(MACE) method, a phase III assay, in which the ELISA plate 
microwells are coated with platelet-specific monoclonal 
antibodies. The Solid Phase ELISA kit (MACE-1, Immucor 
GTI Diagnostics, Waukesha, WI) provides immobilized 
monoclonal antibodies to capture HLA class I and platelet 
GPIIb/IIIa. In the second kit from the same manufacturer 
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(MACE-2, Immucor GTI Diagnostics), the antibodies are 
coated onto the plate to capture GPIb/IX, GPIa/IIa, and GPIV. 
To detect the allogeneic platelet antibodies in the test serum, 
the patient sera are mixed with donor platelets and incubated 
for 30 minutes. Antibody, if present, will bind to the platelet 
glycoproteins. Unbound antibodies are washed from the 
platelets. The antibody-sensitized platelets are solubilized 
by the addition of a lysis buffer solution. The platelet lysate 
containing soluble glycoproteins is transferred to microwells 
for ELISA testing. During ELISA, platelet and HLA class-1 GPs 
would be captured with immobilized monoclonal antibodies 
coated on microwells. After incubation, unbound glycoproteins 
are washed off. An alkaline phosphatase–labeled anti-human 
globulin (AHG) reagent is added and incubated. Unbound AHG 
is washed off. Substrate p-nitrophenyl phosphate (PNPP) is 
added. After 30 minutes of incubation , the reaction is stopped 
by using sodium hydroxide solution. The optical density of 
the color that develops is measured by a spectrophotometer. 
Confirming the presence of these antibodies in patient serum 
would help in the search for potentially compatible platelet 
components.
Results
In our study, we found that 39 of 100 (39%) of multiply 
transfused platelet recipients developed platelet antibodies 
detected by one kit or the other (Immucor GTI Diagnostics), 
of which 11 patients showed refractoriness. Platelet 
refractoriness is a clinical condition in which patients do not 
achieve the anticipated platelet count increment from a platelet 
transfusion. The Trial to Reduce Alloimmunization to Platelets 
study4 defines the refractory state as a CCI of less than 5000 
after two sequential ABO-compatible platelet transfusions. 
Two patients did not develop platelet antibody but they showed 
refractoriness. The number of alloimmmunized patients and 
the percentage manifesting refractoriness are shown in Table 1. 
The rate of refractoriness among our multiply transfused 
patient population is similar to that of other studies, which 
showed an incidence of refractoriness of 5 to 15 percent.5–7
Eleven cases of refractoriness were attributed to 
immunologic causes (i.e., antibody against HLA class I and 
HPA, human platelet antigen), and two cases were a result 
of some nonimmunologic causes including history of fever, 
sepsis, bleeding, and so forth. Of the 11 cases of immunologic 
etiology, two had acute myeloid leukemia, two were 
diagnosed with immune thrombocytopenic purpura (ITP), 
and two had myelodysplastic syndrome. Aplastic anemias, 
acute lymphoblastic leukemia, chronic myeloid leukemia, 
Hodgkin lymphoma, and non-Hodgkin lymphoma (NHL) 
were diagnosed in the remaining five cases. Three patients 
developed only HPA antibody, of which two had ITP and one 
was diagnosed with NHL.
Discussion
The risk of alloimmunization among patients receiving 
multiple platelet concentrate transfusions is one of the major 
issues of current hemotherapy. MACE is an efficient method 
for detection and identification of platelet antibody.
HLA sensitization is the most common immunologic 
cause of platelet refractoriness in multiply transfused patients 
and can be diagnosed by demonstration of significant levels 
of HLA class I antibodies in the refractory patient’s serum 
by MACE-1. When antibodies to HLA class I antigens are 
demonstrating, a widely used approach is to supply apheresis 
platelets from donors whose HLA class I antigens are similar 
to those of the patient. HLA-matched platelets should be 
leukodepleted to reduce the risk of alloimmunization.6,7 
MACE-2 testing has an added advantage of selecting platelets 
when the antibodies involved are directed at platelet-specific, 
rather than HLA, antigens.
An important observation of this study is that in our 
patient population, the most common platelet-specific antibody 
detected was anti-GPIb/IX antibody. This is the first study of 
this kind in India.
Conclusion
In conclusion, MACE-1 and MACE-2 enabled specific 
detection and identification of platelet antibodies, which in 
turn correlated well with the development of refractoriness in 
multiplatelet concentrate–transfused patients. The test should 
specifically be used in patients who have developed platelet 
refractoriness to detect and identify the platelet antibodies.
N. Jain et al.
Table 1. Number of patients who developed refractoriness in the 
population of platelet alloimmmunized patients 
Platelet antibodies against
Number of patients who developed refractoriness/ 




HLA-1 + GPIb/IX 2/5
HLA = human leukocyte antigen; GP = glycoprotein.
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